公开(公告)号：IL249183A

公开(公告)日：2020-11-30

申请号：IL24918316

申请日：2016-11-24

Applicant: ACADEMIA SINICA

IPC: A61K39/395 ,  A61K39/00 ,  A61K39/42 ,  A61K45/06 ,  A61P1/04 ,  A61P3/10 ,  A61P7/00 ,  A61P13/12 ,  A61P17/06 ,  A61P19/02 ,  A61P21/04 ,  A61P25/00 ,  A61P27/02 ,  A61P29/00 ,  A61P31/12 ,  A61P31/14 ,  A61P31/18 ,  A61P31/20 ,  A61P31/22 ,  A61P35/00 ,  A61P35/02 ,  A61P37/02 ,  C07K16/00 ,  C07K16/10 ,  C07K16/18 ,  C07K16/24 ,  C07K16/28 ,  C07K16/30 ,  C07K16/32 ,  C12N9/24 ,  C12P19/14

Abstract: The present disclosure relates to an α-fucosidase having α-(1,2), α-(1,3), α-(1,4), and α-(1,6) fucosidase activity. The present disclosure also relates to the compostions comprising the α-fucosidase, and the methods of producing and using the α-fucosidase in cleaving α-(1,2), α-(1,3), α-(1,4), and/or α-(1,6)-linked fucoses in the glycoconjugates.

公开(公告)号：HUE050104T2

公开(公告)日：2020-11-30

申请号：HUE13819542

申请日：2013-07-19

Applicant: ACADEMIA SINICA ,  UNIV NAT TAIWAN

Inventor： CHEN CHING-CHOW ,  CHEN JHIH-BIN ,  WEI TZU-TANG ,  LIN JUNG-HSIN ,  FANG JIM-MIN ,  CHERN TING-RONG

IPC: A61K31/44 ,  A61K31/47 ,  A61P35/00

公开(公告)号：MX369397B

公开(公告)日：2019-11-07

申请号：MX2014012413

申请日：2013-04-12

Applicant: ACADEMIA SINICA

Inventor： CHI-HUEY WONG ,  JIM-MIN FANG ,  KUNG-CHENG LIU ,  JIA-TSRONG JAN ,  YIH-SHYUN E CHENG ,  TING-JEN R CHENG

IPC: A61K31/35 ,  A61K31/36 ,  A61P29/00 ,  A61P31/16

Abstract: Se describen novedosos fármacos anti-influenza bi-funcionales, de doble enfoque, formados mediante conjugación con agentes anti-inflamatorios. Fármacos ejemplares de acuerdo con la invención incluyen conjugados de zanamivir (ZA) que porta ácido cafeico (CA) ZA-7-CA (1), ZA-7-CA-amida (7) y ZA-7-Nap (43) para inhibición simultánea de neuraminidasa de virus de influenza y supresión de citosinas proinflamatorias. Se proporcionan métodos sintéticos para la preparación de estos fármacos conjugados anti-influenza mejorados. Los conjugados de ZA bifuncionales sintéticos actúan sinérgicamente hacia la protección de ratones infectados letalmente por virus de influenza H1N1 o H5N1. La eficacia de conjugados ZA-7-CA, ZA-7-CA-amida y ZA-7-Nap es mucho mayor que la terapia de combinación de ZA con agentes anti-inflamatorios.

公开(公告)号：RU2696378C2

公开(公告)日：2019-08-01

申请号：RU2017128109

申请日：2016-01-18

Applicant: ACADEMIA SINICA

Inventor： CHANG TSE-WEN ,  CHU HSING-MAO ,  CHEN JOU-HAN ,  LIN CHUN-YU ,  LIN CHIEN-JEN

IPC: C07K16/46 ,  C07K14/485 ,  C07K14/655 ,  C07K14/705 ,  C12P21/08

Abstract: Изобретениеотноситсяк областибиотехнологии, конкретнок линкерномузвену, иможетбытьиспользованов качествесшивающегосредствадляобъединенияразличныхантителилииныхбиологическиактивныхагентовв конъюгатыи построениямолекулярныхконструкцийс конкретнойкомбинациейнацеливающихи эффекторныхэлементовс применениемхимическогосинтеза, либорекомбинантнойтехнологии. 2 з.п. ф-лы, 4 ил., 72 пр.

公开(公告)号：CA2728341C

公开(公告)日：2019-07-02

申请号：CA2728341

申请日：2009-08-06

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  WU CHUNG-YI ,  YU ALICE ,  YU JOHN

IPC: A61K39/00 ,  A61K39/385

Abstract: Immunogenic compositions, cancer vaccines and methods for treating cancer are provided. Compositions compris-ing: (a) a glycan such as Globo H or an immunogenic fragment thereof, wherein the glycan is conjugated with a carrier protein by a linker such as para-nitrophenyl; and (b) an adjuvant comprising glycolipid capable of binding CDId on a dendritic cell, such as an a-galactosyl-ceramide derivative, wherein the immunogenic composition induces an immune response that induces a higher relative level of IgG isotype antibodies as compared to IgM isotype antibodies, are provided. Immunogenic compositions compris-ing the carrier protein diphtheria toxin cross-reacting material 197 (DT-CRM 197) and the adjuvant C34 are provided. Antibodies generated by immunogenic compositions disclosed herein further neutralize at least one of the antigens Globo H, stage-specific embryonic antigen-3 (SSEA-3) and stage-specific embryonic antigen-4 (SSEA-4). Therapeutics against breast cancer stem cells comprising immunogenic compositions comprising Globo H, SSEA-3 or SSEA-4 conjugated with DT-CRM 197.

公开(公告)号：HUE042016T2

公开(公告)日：2019-06-28

申请号：HUE12734706

申请日：2012-01-13

Applicant: UNIV TAIPEI MEDICAL ,  ACADEMIA SINICA

Inventor： YANG WEI-CHUNG ,  WANG HWEI-JIUNG ,  CHEN SHUI-TSUNG ,  LU KEN-FEN ,  PENG MING-CHI

IPC: C12P21/06 ,  G01N33/68

公开(公告)号：IL265248D0

公开(公告)日：2019-05-30

申请号：IL26524819

申请日：2019-03-10

Applicant: ACADEMIA SINICA

IPC: A61K20060101

Abstract: Glycosphingolipids (GSLs) bearing α-glucose (α-Glc) that preferentially stimulate human invariant NKT (iNKT) cells are provided. GSLs with α-glucose (α-Glc) that exhibit stronger induction in humans (but weaker in mice) of cytokines and chemokines and expansion and/or activation of immune cells than those with α-galactose (α-Gal) are disclosed. GSLs bearing α-glucose (α-Glc) and derivatives of α-Glc with F at the 4 and/or 6 positions are provided. Methods for iNKT-independent induction of chemokines by the GSL with α-Glc and derivatives thereof are disclosed. Methods for immune stimulation in humans using GSLs with α-Glc and derivatives thereof are provided.

公开(公告)号：ZA201603118B

公开(公告)日：2019-04-24

申请号：ZA201603118

申请日：2016-05-10

Applicant: ACADEMIA SINICA

Inventor： FANG JIM-MIN ,  LIN YUN-LIAN ,  LIN JUNG-HSIN ,  LIN CHUN-JUNG ,  CHERN YIJUANG ,  HUANG NAI-KUEI ,  WANG HUNG-LI ,  TU BENJAMIN PANG-HSIEN ,  CHEN CHIH-CHENG

Abstract: Compounds for use in prevention and treatment of neurodegenerative disease and pain are disclosed. In one embodiment of the invention, the compound is selected from the group consisting of N6-[(3-halothien-2-yl)methyl]adenosine, N6-[(4-halothien-2-yl)methyl]adenosine, and N6-[(5-halothien-2-yl)methyl]adenosine. In another embodiment of the invention, the compound is selected from the group consisting of N6-[(2-bromothien-3-yl)methyl]adenosine, N6-[(4-bromothien-3-yl)methyl]adenosine, N6-[(5-bromothien-3-yl)methyl]adenosine N6-[(2-chlorothien-3-yl)methyl]adenosine, N6-[(4-chlorothien-3-yl)methyl]adenosine, and N6-[(5-chlorothien-3-yl)methyl]adenosine. Also disclosed are methods of making and using the same.

公开(公告)号：CA2781433C

公开(公告)日：2019-04-09

申请号：CA2781433

申请日：2010-11-19

Applicant: ACADEMIA SINICA

Inventor： LIANG SHU-MEI ,  CHIU CHING-FENG ,  HUNG SHAO-WEN ,  PENG JEI-MING ,  LIANG CHI-MING

IPC: A61K38/38 ,  A61K38/16 ,  A61P35/04 ,  C07K14/09 ,  C07K14/76

Abstract: Methods are provided for suppressing cancer metastasis. Cancer metastasis is the most common cause of treatment failure and death in cancer patients. Tumor cell invasion and/or migration can be significantly inhibited after fibrillar proteins (rVP1, F-HSA, and F-BSA) treatment in vitro. In addition, rVP1 can significantly suppress murine and human breast cancer metastasis and human prostate and ovarian cancer metastasis in vivo while F-HSA can significantly suppress murine breast cancer metastasis. Compositions of fibrillar proteins as anti-cancer metastasis therapeutics and methods of use thereof are provided herein.

公开(公告)号：ES2704978T3

公开(公告)日：2019-03-21

申请号：ES12734706

申请日：2012-01-13

Applicant: UNIV TAIPEI MEDICAL ,  ACADEMIA SINICA

Inventor： YANG WEI-CHUNG ,  WANG HWEI-JIUNG ,  CHEN SHUI-TSUNG ,  LU KEN-FEN ,  PENG MING-CHI

IPC: C12P21/06 ,  G01N33/68

Abstract: Un anticuerpo monoclonal que se une específicamente a un epítopo de una isoforma de alfa 1-antitripsina (A1AT) que tiene un peso molecular de aproximadamente 72 kDa o 58 kDa, en el que el epítopo consiste de una secuencia de aminoácidos de la SEQ ID NO: 27.